A pilot study of neuroblastoma mass screening was initiated in January 1990 in the Rhone French district.
The expected number of births per year is 26,000.
The study is designed for a 5-year period with three major goals : 1) measurement of the compliance rate of a voluntary test at 4 months of age ; 2) evaluation of the technical value of high-pressure liquid chromatography (HPLC) as a screening method ; and 3) detailed biological characterization of all detected tumors. 61,551 children were screened between May 1,1990 and December 31,1993.
Participation was 69% in 1990,81.5% in 1991, and over 83% in 1992.
HPLC was a satisfactory assay method.
The number of clinical examinations required for positive tests as defined in the protocol is 1 per 3,621 tests.
The false positive rate is 1 per 3,583 tests.
Eight neuroblastomas were discovered by-screening (one stage I, three stage II, one stage III, three stage IVs).
All are alive and well but were good prognosis cases according to the main prognostic factors.
Five patients were discovered before screening (so called Halo effect) : one stage I, one stage III, three stage IVs.
One died of disease and four are alive in complete remission after treatment.
Two patients were false negative (one stage III with N-myc amplification, one stage IV with bad prognosis features) and three cases of neuroblastoma were missed because of noncompliance with the screening program. (...)
Mots-clés Pascal : Neuroblastome, Enfant, Homme, Nourrisson, Dépistage, Prévention, Epidémiologie, Vanilmandélique acide, Urine, Chromatographie HPLC, Programme sanitaire, Méthodologie, Résultat, Rhône, Rhône Alpes, France, Europe, Echelon régional, Diagnostic, Stade précoce, Analyse biochimique, Système nerveux pathologie, Système nerveux sympathique pathologie, Tumeur maligne, Homovanillique acide
Mots-clés Pascal anglais : Neuroblastoma, Child, Human, Infant, Medical screening, Prevention, Epidemiology, Vanillyl mandelic acid, Urine, HPLC chromatography, Sanitary program, Methodology, Result, Rhône, Rhône Alpes, France, Europe, Regional scope, Diagnosis, Early stage, Biochemical analysis, Nervous system diseases, Autonomic neuropathy, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0081743
Code Inist : 002B17E. Création : 21/05/1997.